AI has shown promise by analysing data from patient records to recognise complex patterns within large datasets, which can aid in the ...

Patients can be also classified according to response to treatment as refractory when ... who met the classification criteria for the diagnosis of JDM [15 15 Bohan A, Peter JB. Polymyositis and ...

Methods: Patients with inflammatory myositis of recent onset who had not received treatment were evaluated for ... Two patients with polymyositis had cardiac clinical symptoms. Two other patients with ...

Idiopathic inflammatory myopathies (IIM) include a heterogenous group of rare disorders including dermatomyositis ... biomarkers for early diagnosis complicates disease management and underscores the ...

The FDA has approved an antibiotic called minocycline for the treatment of rosacea in adults. The drug, which is taken orally ...

Kawasaki disease (KD), an acute self-limited febrile illness that primarily affects children <5 years old, is the leading cause of acquired heart disease in developed countries, with the potential of ...

“JIA can take a heavy toll on the lives of affected children and families,” said Daniel Horton, a faculty member at the ...

Engineered polymers interfere with protein interactions to protect cell health in a mouse study. Researchers at Northwestern University and Case Western Reserve University have developed the first ...

Johnson & Johnson (NYSE: JNJ) announced today that 43 presentations showcasing the Company's rheumatology pipeline and portfolio will be featured at the American College of Rheumatology (ACR) 2024 ...

A strict life-long gluten-free diet is the only safe and efficient available treatment, yet it results in a social burden. Alternative treatment modalities focus on modification of dietary ...

Patients who are evaluated through the ADMDC should expect to have their options for treatment identified and explained to them so that they may make a well informed decision about their care. If a ...

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.